Biogen (NASDAQ:BIIB) announced the enrollment of the last patient in the company’s global Phase 3 STAR clinical study.
The study is aimed at evaluating the investigational gene therapy timrepigene emparvovec (BIIB111/AAV2-REP1) for the treatment of choroideremia.
Biogen believes timrepigene emparvovec could be a transformative gene therapy for individuals living with choroideremia who would otherwise face inevitable blindness.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.